Amgen Slides 9% as Novartis Lp(a) Failure Hits a Whole Class

Amgen shares fell 9.15% to 397.22 and Novartis dropped 13.97% to 137.64 by 17:45 GMT on September 8, 2026, after a Novartis trial failure in lipoprotein(a) lowering clouded the emerging cholesterol drug class, even as Amgen reported promising data of its own the same morning.

One trial result reset the market's view of an entire cholesterol franchise on Monday. Novartis (NVS) reported a failure in its lipoprotein(a) program, and investors did not treat it as a company-specific stumble. They treated it as a verdict on the science. By 17:45 GMT on September 8, 2026, Novartis shares were quoted at 137.64 in licensed market data, down 13.97% from the prior close of 159.99, having traded as low as 137.47 on the session.

The heavier surprise was what happened to the other side of the trade. Amgen (AMGN), which put out promising results from its own Lp(a)-lowering effort the same morning, fell alongside the failure rather than rallying against it. Amgen changed hands at 397.22, down 9.15% from a prior close of 437.23, with a session range of 392.00 to 411.06. Good data and a double-digit percentage decline arrived in the same news cycle.

Why a rival's failure dragged Amgen down with it

Lipoprotein(a), usually written Lp(a), is a cholesterol-carrying particle whose level in the blood is set largely by inherited genetics. Diet, statins and the newer LDL-lowering drugs barely touch it. That makes it one of the last widely recognized cardiovascular risk factors with no approved therapy aimed at it, and it explains why several large drugmakers have spent years building programs designed to knock Lp(a) down sharply.

The catch has always been the step after the biology. Investors have long known these drugs can lower the particle. What they have not known is whether lowering it prevents heart attacks and strokes. That is the question a cardiovascular outcomes trial answers, and it is the question on which the commercial case rests. A drug that moves a blood marker without changing outcomes is a science paper, not a franchise.

When Novartis reported that its trial had failed, the market drew the broader inference: perhaps the Lp(a) hypothesis itself, not one molecule's execution, is what came up short. Under that reading, Amgen's encouraging data becomes less valuable, because the endpoint that matters most for the class has just been called into question by a competitor's read. Hence a 13.97% fall for the company with the failure and a 9.15% fall for the company with the good news, as reported by 24/7 Wall St.

A class trade, not a stock trade

Drug classes get priced as blocks more often than investors admit. When one asset in a mechanism succeeds, the peers rise; when one fails on the endpoint that defines the category, the peers fall regardless of their own numbers. That is what Monday looked like. The correlation runs through the biology, not the balance sheet.

The asymmetry is worth noting. Novartis lost more in percentage terms, which is what you expect from the company that owns the failure. But Amgen's decline is the more informative one, because it says the market is discounting a program that reported well. In effect, traders decided that Amgen's own readout was not enough to insulate it from a negative signal about whether the target works at all.

The wider tape offered no cover. The S&P 500, via SPY, sat at $767.40, down 0.36% from a prior close of $770.19. The Dow 30, via DIA, was at $528.83, off 0.98%. The Nasdaq 100, via QQQ, was slightly higher at $719.94, up 0.14%. Index moves under one percent do not explain double-digit declines in two large-cap pharmaceutical names. This was idiosyncratic, and it was about the drugs.

What the two readouts leave unresolved

Nothing in Monday's price action settles the science. A failed trial in one program does not automatically doom a mechanism; differences in molecule design, dosing, patient selection, baseline Lp(a) levels and trial duration can all separate one result from another. Amgen's promising data exists on its own terms and does not disappear because a competitor missed.

What has changed is the burden of proof. Before Monday, the class carried the benefit of the doubt on outcomes. After Monday, Amgen has to demonstrate that its own outcomes evidence holds where a rival's did not, and it has to do so in front of a market that has just shown how quickly it will reprice the whole group on a single data point.

Several things determine whether these moves stick:

• The detail behind the Novartis miss — whether it looks like a molecule or trial-design problem, or a challenge to the Lp(a) hypothesis itself.
• How Amgen's own results read against the specific endpoint Novartis failed.
• Whether other companies with Lp(a) assets in development update their plans, timelines or guidance.
• How cardiology opinion leaders characterize the failure once the full data are presented and scrutinized.

The read-across for pipeline valuations

For investors, the episode is a reminder of how much of a large drugmaker's share price can rest on an unproven mechanism. Amgen and Novartis both have broad, diversified revenue bases, and yet a single trial in a single therapeutic category moved both by high single or double digits in a session. That is a statement about how far forward expectations had been pulled, not about current sales.

It also underlines a practical point about holding two names in the same mechanism. Owning the leader and the challenger in an emerging drug class feels like diversification and is not. When the risk is the biology, both positions carry the same exposure, and both settle on the same day.

Prices cited are intraday as of the last trade at 17:45 GMT on September 8, 2026, and will change as the session continues.

Key facts

• AMGN price: 397.22, -9.15% (as of 17:45 GMT, Sep 8, 2026)
• NVS price: 137.64, -13.97% (as of 17:45 GMT, Sep 8, 2026)
• Prior closes: AMGN 437.23; NVS 159.99
• Trigger: Novartis Lp(a) trial failure; Amgen reported promising data the same morning

Frequently asked questions

What is lipoprotein(a) and why do drugmakers target it?

Lipoprotein(a), or Lp(a), is a cholesterol-carrying particle in the blood whose level is largely inherited. Statins and standard LDL-lowering drugs have little effect on it, so it remains a recognized cardiovascular risk factor without an approved therapy aimed at it. That gap is why several large pharmaceutical companies have built development programs designed to lower it sharply.

How far did Amgen and Novartis shares fall?

As of the last trade at 17:45 GMT on September 8, 2026, Amgen was quoted at 397.22, down 9.15% from a prior close of 437.23, with a session range of 392.00 to 411.06. Novartis traded at 137.64, down 13.97% from a prior close of 159.99, having reached a session low of 137.47.

Why did Amgen fall if its own trial results were promising?

Investors treated the Novartis failure as a signal about the whole Lp(a) drug class rather than one company's misstep. If lowering Lp(a) does not clearly reduce cardiovascular events, the commercial value of every program targeting it shrinks. Under that reading, Amgen's encouraging data was not enough to offset doubt about whether the underlying target works.

Does the Novartis failure mean the Lp(a) approach is dead?

No. Differences in molecule design, dosing, patient selection, baseline Lp(a) levels and trial duration can separate one result from another, so a single miss does not automatically condemn a mechanism. What has changed is the burden of proof: Amgen now has to show its own outcomes evidence holds where a competitor's did not.

Was the broader market responsible for the declines?

No. As of 17:45 GMT on September 8, 2026, SPY was at $767.40, down 0.36%, DIA at $528.83, down 0.98%, and QQQ at $719.94, up 0.14%. Index moves under one percent cannot account for high single-digit and double-digit falls in two large pharmaceutical stocks. The moves were company- and class-specific.

What should investors watch next in this drug class?

Key items are the detailed data behind the Novartis miss and whether it points to a molecule or trial-design issue rather than the Lp(a) hypothesis; how Amgen's results read against the endpoint Novartis failed; any timeline or guidance changes from other developers with Lp(a) assets; and how cardiology specialists interpret the full dataset once presented.

Sources

• Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14% — 24/7 Wall St

Photo: https://kaboompics.com/ · Pexels Licence — source